Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025 CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, November 6th. Management will host a conference call at 5:00 p.m. East...
Organogenesis Provides Update on Second Phase 3 ReNu® Study Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpointStatistically significant maintenance of function (p
A director at Prudential bought 13,000 shares at 966p and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Prudential’s 1H25 results were broadly within our expectations with NBP growing at 12% yoy, mainly driven by Hong Kong, Indonesia and China. OPAT per share and gross OSFG were ahead of our estimates. On its capital management update, Prudential announced its DPS to grow over 10% in 2025-27, additional US$1.1b buybacks in 2026-27 and return of excess capital above 200% of free surplus ratio, implying over 5% yield in 2025-27. Maintain BUY. Target price: HK$128.00.
KEY HIGHLIGHTS Results Anhui Conch Cement (914 HK/BUY/HK$24.46/Target: HK$28.90) Anhui Conch Cement reported 1H25 earnings of Rmb4,367.9m (+31.3% yoy), representing 42.5% of our full-year estimates, slightly above expectations. Gross margin for self-produced products rose to 28.9% (+5.8ppt yoy). Cement ASP edged up 1.5% yoy, while unit production cost fell 7.1% yoy, mainly on a 13.8% drop in fuel and power costs. Cement and clinker sales volume was broadly stable at 126mt (-0.4% yoy), outperfo...
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September CANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences: The Cantor Fitzgerald Global Healthcare Conference at the New York Marriott Marquis in New York, NY Management will partic...
Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared...
We expect Prudential to deliver 12% yoy NBP growth in 1H25, in line with management guidance, mainly driven by solid sales growth and continued margin expansion. The key point in its 1H25 results will be the capital management policy, and we expect Prudential to provide more clarity on its regular payout and planned use of net proceeds from the partial sale of its stake in IPAMC, which is likely to offer additional shareholder returns. Maintain BUY. Target price: HK$128.00.
KEY HIGHLIGHTS Results ASMPT (522 HK/BUY/HK$63.20/Target: HK$92.40) ASMPT’s 2Q25 results were largely in line, with revenue at the mid-point of its guided range, while bookings were a solid beat thanks to a bulk order from smartphone clients. The sustained improvement in orders momentum likely signals the beginning of a new capex cycle, while ongoing advances in AI-related products will likely bolster investor confidence in the near term. Maintain BUY and raise target price to HK$92.40. Upda...
Results ASMPT (522 HK/BUY/HK$63.20/Target: HK$92.40): 2Q25: Results largely in line. Solid bookings beat as mainstream tools recover; AP tools progressing well in logic and at HBM clients. Update Prudential (2378 HK/BUY/HK$98.10/Target: HK$128.00): 1H25 results preview: Expecting solid NBP growth and focusing on capital management. INDONESIA Small/Mid Cap Highlights Medco Energi Internasional (MEDC IJ/NOT RATED/Rp1,260): Disciplined strategy and portfolio diversification. MALAYSIA Update CIMB ...
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025 CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Easter...
Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds the Centers for Medicare & Medicaid Services’ (CMS) proposed new payment approach for skin substitutes/cellular and tissue-based ...
Blue Sky Territory; Bullish Outlook Intact We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). Our near-term bullish outlook will remain in place long as the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM) are above their 20-day MAs. We will maintain our bullish intermediate-term outlook as long as market dynamics remain healthy and the SPX is above 5700-5785. Short-term support on SPX is at 6028-6...
China regulators have introduced several measures, allowing insurers to further raise their equity investment allocations. We estimate that insurers could reallocate Rmb900b to equities, supported by these regulatory tailwinds. However, insurers are likely to remain cautious due to earnings volatility and solvency headwinds from a declining long-term yield. Maintain MARKET WEIGHT. Top picks: Prudential and PICC P&C.
GREATER CHINA Sector Insurance Weighing the risks and returns. Update Sunny Optical (2382 HK/BUY/HK$65.15/Target: HK$100.00) Takeaways from 2025 Investor Day. Maintain BUY. INDONESIA Strategy Challenging Macro Environment Adds To Case For Rate Cut Our top picks are BBCA, BBRI, ANTM, AMRT, ICBP, CMRY and ERAA. MALAYSIA Sector Automobile ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.